Israel’s Compugen (see here previously) only had six months’ cash left when it was rescued by Gilead Sciences in a deal worth up to $848 million. Gilead will license Compugen’s pre-clinical cancer antibody COM503 that frees up the peptide InterLeukin … Continue reading →

Israeli cancer immunotherapy company Compugen is to provide its pipeline of cancer-fighting antibodies to MedImmune – AstraZeneca’s global biologics research and development arm. Compugen will initially receive $10 million and then up to $200 million for the first MedImmune product. … Continue reading →

Israeli biotech Compugen has enlisted John Hopkins University to help assess Compugen’s cancer immunotherapy candidates.  These new treatments aim to counter the ability of tumors to highjack “immune checkpoints”, thereby blocking the immune system’s ability to destroy the tumor. http://www.israel21c.org/news/compugen-teams-with-johns-hopkins-university-on-immune-checkpoints/

Israeli biotech Compugen announced that the protein CGEN-15022, discovered by the company, has the potential for treating liver, colorectal, lung and ovarian cancers through monoclonal antibody (mAb) therapy. http://www.globes.co.il/serveen/globes/docview.asp?did=1000760767&fid=1725

I reported in May that Israeli biotech Compugen discovered 4 new protein variants that stimulate the immune system into targeting cancer cells. Now tests have shown that CGEN-15001T will fight carcinomas, sarcomas, melanoma and haematological cancers. http://www.globes.co.il/serveen/globes/docview.asp?did=1000721404&fid=1725

Israeli biotech Compugen has tied up with the US DiscoveRx Corporation in order to find more peptides (short amino acids) that have therapeutic properties. Compugen’s innovative technology has already discovered peptides to treat cardiovascular, fibrotic and inflammatory conditions. http://www.globes.co.il/serveen/globes/docview.asp?did=1000702178&fid=1725